Drug combination for treating obesity
AssigneeThe Curators of the University of Missouri
InventorsVictoria J. Vieira-Potter, Dennis B. Lubahn, Eric D. Queathem
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating obesity, pre-diabetes, diabetes, and/or obese breast cancer, by increasing mitochondrial metabolism by increasing the activity of uncoupling protein 1 (UCP1) in adipocytes. The disclosed methods comprise contacting an adrenergic receptor agonist with an adipocyte in which the genomic activity of estrogen receptor beta (ERβ) has been inhibited or inactivated. In certain aspects, inhibition or inactivation of the genomic activity of ERβ is achieved by contacting the adipocyte with an ERβ ligand that selectively inhibits or inactivates the ERβ genomic activity.
Claims22
A therapeutic composition comprising a beta 3 adrenergic receptor (β3AR) agonist and an estrogen receptor beta (ERβ) ligand.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of increasing or enhancing transcription of uncoupling protein 1 (UCP1) in an adipocyte or increasing the metabolism of an adipocyte, comprising contacting the adipocyte with a beta 3 adrenergic receptor (β3AR) agonist and an estrogen receptor beta (ERβ) ligand.
Dependencies are inferred from the claim text.